Scholar Rock (NASDAQ:SRRK – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.11), Briefing.com reports. During the same quarter last year, the business posted ($0.46) earnings per share.
Scholar Rock Stock Down 2.5 %
Shares of Scholar Rock stock opened at $14.69 on Wednesday. Scholar Rock has a 12-month low of $5.56 and a 12-month high of $21.17. The stock has a market capitalization of $1.17 billion, a P/E ratio of -7.38 and a beta of 0.94. The company has a quick ratio of 8.80, a current ratio of 8.80 and a debt-to-equity ratio of 0.22. The stock has a 50 day moving average price of $15.20 and a two-hundred day moving average price of $14.95.
Insider Transactions at Scholar Rock
In related news, insider Mo Qatanani sold 2,512 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $39,538.88. Following the transaction, the insider now directly owns 147,019 shares in the company, valued at approximately $2,314,079.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Mo Qatanani sold 2,512 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.74, for a total transaction of $39,538.88. Following the completion of the sale, the insider now owns 147,019 shares in the company, valued at approximately $2,314,079.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jay T. Backstrom sold 11,614 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.74, for a total value of $182,804.36. Following the completion of the sale, the chief executive officer now directly owns 352,671 shares in the company, valued at approximately $5,551,041.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,359 shares of company stock worth $351,931. 26.20% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Report on Scholar Rock
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Recommended Stories
- Five stocks we like better than Scholar Rock
- 3 Small Caps With Big Return Potential
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
- How to Capture the Benefits of Dividend Increases
- Chegg Chokes on AI Attempt, CEO Talks it Up As He Passes Torch
- Investing in Commodities: What Are They? How to Invest in Them
- Does Logitech’s EPS Beat Signal the Rebound of Video Gaming?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.